Biosynthetic hyaluronic acid

01Overview and value chain

Markers: [EC: USP / Ph. Eur. pharmacopoeia monographs for hyaluronic acid | OECD: Industrial biotechnology — biosynthetic HA | Regulator: FDA (USA), EMA (EU), NMPA (China)]

Biosynthetic hyaluronic acid (HA) is the high-margin, microbial-fermentation route to a unique glycosaminoglycan that binds up to 1000 times its weight in water. It replaces the legacy animal-tissue extraction (rooster combs, mammalian umbilical cords) that carried prion and viral risk with a vegan, endotoxin-controlled biopolymer from recombinant Bacillus subtilis or Saccharomyces cerevisiae, tuned to a precise molecular weight from 10 kDa low-MW actives up to more than 2.5 MDa ultra-high-MW viscoelastics. The industry is one of the highest-margin corners of biopharma and cosmetics: AbbVie’s Allergan aesthetics portfolio reported $4.86 billion in 2025 revenue with the Juvederm HA-filler line at $993 million, Galderma reached $5.21 billion in 2025 net sales (up 17.7% constant currency), and Bloomage Biotech holds the leading share of the Chinese HA raw-material market. HA is sold as a B2B active into four segments: ophthalmic viscoelastics for cataract surgery, cross-linked dermal fillers for aesthetic medicine, viscosupplementation injections for knee osteoarthritis, and premium hydrating cosmetics. Every medical-grade batch is held to pharmacopoeia monographs (USP / Ph. Eur.) with endotoxin below 0.05 EU/mg, under FDA in the US, EMA in Europe and NMPA in China.

The key directions of biosynthetic hyaluronic acid are:

1. Precision microbial fermentation for a defined molecular weight: recombinant B. subtilis (hasA) and S. cerevisiae strains with precursor-pathway genes (tuaD, gtaB) that let the fed-batch be steered to a target chain length, from 10 kDa oligomers to more than 2.5 MDa ultra-high-MW polymer.
2. Apyrogenic downstream purification: activated-carbon adsorption and ultrafiltration/diafiltration that strip bacterial lipopolysaccharide endotoxins to below 0.05 EU/mg for injectable pharmacopoeia grade.
3. Cross-linked HA hydrogels: BDDE and similar cross-linkers that turn linear HA into a resistant hydrogel with prolonged tissue residence for dermal fillers and viscoelastics.
4. Targeted application formulation: ophthalmic viscoelastics (cataract), single-injection viscosupplementation (knee osteoarthritis), cross-linked dermal fillers (aesthetics) and low-MW hydrating serums (premium cosmetics).

Sectoral value chain

[Strain engineering] ──> [Fed-batch fermentation] ──> [Cell-free clarification]
        │                          │                          │
(recombinant hasA, tuaD,     (B. subtilis, 50 m³,       (centrifuge + 300 kDa
 precursor balance)           48 h, viscosity >2000 cP)  ultrafiltration)
                                                        │
                                                        ▼
[B2B aseptic fill] <─── [Ethanol precipitation] <─── [Endotoxin adsorption]
(lyophilized, ISO 5)       (3 vol ethanol, +4 °C)       (carbon, <0.05 EU/mg)

Value chain levels

Cross-cutting technologies of the sector:

• Target-molecular-weight HA synthesis: precise dosing of carbon and nitrogen controls the intracellular UDP-glucuronic-acid to UDP-GlcNAc ratio, which sets the polymer chain length, so one strain platform can output anything from 10 kDa oligomers to more than 2.5 MDa ultra-high-MW polymer.
• Apyrogenic downstream purification: activated-carbon beds plus 100 kDa-cutoff ultrafiltration remove trace bacterial lipopolysaccharides that would trigger inflammatory injection reactions, holding endotoxin below 0.05 EU/mg.
• Cross-linked HA hydrogels: agents such as BDDE cross-link HA chains into a 3D network that resists enzymatic hyaluronidase degradation, extending dermal-filler and viscoelastic residence from days to months.

02US

The United States leads the high-value, FDA-regulated injectable segment, where large pharma buys ultra-pure HA API and cross-links it into premium aesthetics and orthopedic viscosupplementation products.

Aesthetics fillers (AbbVie/Allergan), orthopedic viscosupplementation (Anika), FDA USP-grade control

• AbbVie (Allergan, Juvederm): AbbVie’s Allergan aesthetics portfolio reported $4.86 billion in 2025 revenue, with the Juvederm cross-linked HA filler line at $993 million; AbbVie buys ultra-pure HA API and formulates cross-linked hydrogels with prolonged tissue residence.
• Anika Therapeutics (Nasdaq: ANIK): Anika is a global leader in osteoarthritis pain management and early-intervention regenerative orthopedics, reporting full-year 2025 results with HA-based viscosupplementation (Monovisc, Cingal) for knee osteoarthritis.
• FDA and USP-grade control: the FDA regulates injectable HA as a device/drug under USP pharmacopoeia monographs, and US buyers demand the highest-purity, cross-linkable HA API for premium gel formulations.

03CN

China is the volume pole of global HA, controlling the majority of world raw-material output and driving HA down to commodity B2B cost, anchored by Bloomage Biotech in Jinan and a new Tianjin biosynthesis plant.

Bloomage Biotech volume leadership, commodity HA, hyaluronidase oligomer fractionation

• Bloomage Biotech: Bloomage Biotech holds the leading share of the Chinese HA raw-material market, operating major biosynthesis capacity in Jinan (Shandong) and a new Tianjin plant, and is pivoting from commodity HA into glycoscience and AI-designed glycans for higher-value applications.
• Commodity B2B HA: Chinese producers radically cut the cost of food- and cosmetic-grade HA, turning it into a mass B2B raw material and supplying the global filler and cosmetics industry with API.
• Hyaluronidase fractionation: Chinese R&D actively patents enzymatic (hyaluronidase) cleavage of HA into oligomeric low-MW fractions for cosmetic penetration, and the NMPA registers HA-based medical devices under the national device regime.

04EU

The European Union leads the solvent-free, GMP-grade medical HA segment — anchored by HTL Biotechnology in France — and pairs it with two large HA-product brands in Galderma (Switzerland) and Fidia (Italy).

HTL Biotechnology (France), Galderma (Switzerland), Fidia (Italy), GMP + HA-collagen implants

• HTL Biotechnology: HTL Biotechnology in Brittany (a more than 64,000 m² site) is a global leader in pharmaceutical-grade biopolymers, running fermentation through extraction and purification on a solvent-free route and inaugurating a new sterile hyaluronic-acid production line on 6 June 2025.
• Galderma (Restylane, SIX: GALD): Galderma, the pure-play dermatology category leader, delivered record 2025 net sales of $5.21 billion (up 17.7% constant currency) with core EBITDA of $1.21 billion, anchored by the Restylane cross-linked HA filler line.
• Fidia Farmaceutici (HYMOVIS, Hyalgan): Italian Fidia won FDA approval for HYMOVIS ONE, a single-injection hyaluronan therapy for knee osteoarthritis launched at AAOS 2026, and runs the established Hyalgan viscosupplementation line, while EU R&D develops HA–recombinant-collagen combination implants for tissue regeneration.

05Leading companies and research institutes

06Tech stack and innovations

The biosynthetic-HA stack joins a recombinant strain-and-fermentation core, an apyrogenic downstream purification train, and a cross-linking / aseptic formulation layer.

1. Recombinant strain and fed-batch fermentation:
   • A B. subtilis WB800 host carries the Streptococcus hasA hyaluronan synthase with the precursor-pathway genes tuaD and gtaB, so the UDP-glucuronic-acid to UDP-GlcNAc ratio can be held near 1.0 to push the longest chains.
   • Fed-batch fermentation runs roughly 48 hours in a 50 m³ bioreactor at 37 °C with Intermig impellers for the viscous broth (>2000 cP) and high aeration to prevent oxygen starvation.
2. Apyrogenic downstream purification:
   • Activated-carbon filter-presses and endotoxin-removal membranes (e.g. Pall) drop bacterial lipopolysaccharide below 0.05 EU/mg, the bar for injectable pharmacopoeia grade.
   • Three volumes of chilled anhydrous ethanol precipitate the fibrous sodium hyaluronate, recovered by centrifugation and ethanol-washed.
3. Cross-linking and aseptic formulation:
   • BDDE-type cross-linkers convert linear HA into a 3D hydrogel that resists hyaluronidase, extending dermal-filler and viscoelastic residence.
   • The fiber is vacuum freeze-dried at −20 °C, aseptically milled, and double-bag filled under ISO 5 / Class A with nitrogen back-fill for B2B API shipment.

07Value chains and production pipelines

Production pipeline of injectable pharmacopoeia-grade HA (USP / Ph. Eur., GMP)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Fed-batch fermentation │ ───> │ 2. Cell separation &      │
│    (B. subtilis hasA)     │      │    300 kDa ultrafiltration│
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Ethanol precipitation  │ <─── │ 3. Endotoxin adsorption   │
│    (3 vol, +4 °C)         │      │    (carbon, <0.05 EU/mg)  │
└───────────────────────────┘      └───────────────────────────┘
               │
               ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Lyophilization &       │ ───> │ 6. QC release             │
│    aseptic fill (ISO 5)   │      │    (HPLC-GPC MALS, LAL)   │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Fed-batch fermentation

The recombinant B. subtilis hasA strain is cultivated in a 50 m³ bioreactor at 37 °C with glucose and glutamine feeds every two hours; Intermig impellers and high aeration manage the broth viscosity above 2000 cP over a roughly 48-hour run.

Stage 2: Cell separation and ultrafiltration

The culture broth is diluted to cut viscosity, run through tubular centrifuges to remove cells, and the filtrate is concentrated on 300 kDa ultrafiltration membranes that retain the high-MW HA polymer.

Stage 3: Endotoxin adsorption

The HA solution passes through a cascade of activated-carbon filter-presses and endotoxin-removal membrane cartridges, dropping pyrogen levels below 0.05 EU/mg for injectable pharmacopoeia grade.

Stage 4: Ethanol precipitation

Three volumes of chilled (+4 °C) anhydrous ethanol are dosed into the purified solution under continuous mixing; the fibrous sodium-hyaluronate precipitate is recovered by centrifugation and washed with ethanol.

Stage 5: Lyophilization and aseptic fill

The fibers are vacuum freeze-dried at −20 °C, milled in an aseptic mill, and double-bagged in sterile polyethylene pouches under ISO 5 / Class A with nitrogen back-fill to prevent oxidative degradation.

Stage 6: QC release

Each lot is tested by HPLC size-exclusion chromatography with multi-angle light scattering (HPLC-GPC MALS) for molecular-weight distribution, and by LAL assay for residual endotoxin, before release as pharmacopoeia-grade B2B API.